Abstract:We demonstrate that Mycobacterium tuberculosis recombinant leucine-responsive regulatory protein (rLrp) inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-α), interleukin-6, and interleukin-12 production and blocks the nuclear translocation of subunits of the nuclear-receptor transcription factor NF-κB (Nuclear factor-kappa B). Moreover, rLrp attenuated LPS-induced DNA binding and NF-κB transcriptional activity, which was accompanied by the degradation of inhibitory IκBα and a consequent decrease in the nuclear translocation of the NF-κB p65 subunit. RLrp interfered with the LPS-induced clustering of TNF receptor-associated factor 6 and with interleukin-1 receptor-associated kinase 1 binding to TAK1. Furthermore, rLrp did not attenuate proinflammatory cytokines or the expression of CD86 and major histocompatibility complex class-II induced by interferon-gamma in the macrophages of Toll-like receptor 2 deletion (TLR2 −/− ) mice and in protein kinase b (Akt)-depleted mouse cells, indicating that the inhibitory effects of rLrp were dependent on TLR2-mediated activation of the phosphatidylinositol 3-OH kinase (PI3K)/Akt pathway. RLrp could also activate the PI3K/Akt pathway by stimulating the rapid phosphorylation of PI3K, Akt, and glycogen synthase kinase 3 beta in macrophages. In addition, 19 amino acid residues in the N-terminus of rLrp were determined to be important and required for the inhibitory effects mediated by TLR2. The inhibitory function of these 19 amino acids of rLrp raises the possibility that mimetic inhibitory peptides could be used to restrict innate immune responses in situations in which prolonged TLR signaling has deleterious effects. Our study offers new insight into the inhibitory mechanisms by which the TLR2-mediated PI3K/Akt pathway ensures the transient expression of potent inflammatory mediators.

Epigenetically modulated LRRC33 acts as a negative physiological regulator for multiple Toll-like receptors.

LRRC14 Attenuates Toll-like Receptor-Mediated NF-κB Signaling Through Disruption of IKK Complex.

Identification and characterization of a unique leucine-rich repeat protein (LRRC33) that inhibits Toll-like receptor-mediated NF-κB activation.

MicroRNA-92a Negatively Regulates Toll-like Receptor (TLR)-triggered Inflammatory Response in Macrophages by Targeting MKK4 Kinase

Inducible Microrna-223 Down-Regulation Promotes Tlr-Triggered Il-6 And Il-1 Beta Production In Macrophages By Targeting Stat3

E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2

Negative regulator NLRC3: Its potential role and regulatory mechanism in immune response and immune-related diseases

Integrin CD11b Negatively Regulates TLR9-triggered Dendritic Cell Cross-Priming by Upregulating Microrna-146A.

Microrna-487b Is A Negative Regulator Of Macrophage Activation By Targeting Il-33 Production

Lysosome-Associated Small Rab Gtpase Rab7b Negatively Regulates Tlr4 Signaling In Macrophages By Promoting Lysosomal Degradation Of Tlr4

Histone lysine methyltransferase Ezh1 promotes TLR-triggered inflammatory cytokine production by suppressing Tollip

TLR5S Negatively Regulates the TLR5M-mediated NF-κB Signaling Pathway in Epinephelus Coioides.

Modulation of Toll–interleukin 1 receptor mediated signaling

The Gut Epithelial Receptor LRRC19 Promotes the Recruitment of Immune Cells and Gut Inflammation.

A Negative Feedback Loop of ICER and NF-κB Regulates TLR Signaling in Innate Immune Responses

ZCCHC3 modulates TLR3-mediated signaling by promoting recruitment of TRIF to TLR3

NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling Pathways

DCIR Negatively Regulates CpG-ODN-induced IL-1β and IL-6 Production.

TLR10 Is a Negative Regulator of Both MyD88-Dependent and -Independent TLR Signaling

NLRX1 Negatively Regulates TLR-Induced NF-κB Signaling by Targeting TRAF6 and IKK

The Rlrp of Mycobacterium Tuberculosis Inhibits Proinflammatory Cytokine Production and Downregulates APC Function in Mouse Macrophages Via a TLR2-mediated PI3K/Akt Pathway Activation-Dependent Mechanism